Advertisement
Novartis
Subscribe to Novartis

The Lead

Novartis Top Management Quits Over Involvement in Clinical Study

April 3, 2014 8:04 am | News | Comments

Novartis Pharma K.K. said Thursday its president Yoshiyasu Ninomiya and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.     

Effectiveness Prompts Novartis to End Drug Study

March 31, 2014 10:26 am | by The Associated Press | News | Comments

Novartis said it's cutting off late-stage research into a potential chronic heart failure...

FDA Approves Xolair for Chronic Idiopathic Urticaria

March 24, 2014 8:25 am | News | Comments

The FDA has approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria (CIU...

Novartis Provides Second US University with Bexsero

February 24, 2014 8:16 am | News | Comments

Novartis announced today that its meningococcal serogroup B (MenB) vaccine, Bexsero (...

View Sample

FREE Email Newsletter

Novartis Case Linked to Structural Problems Between Doctors, Industry

February 20, 2014 8:02 am | News | Comments

The manipulation of clinical research data for a blood pressure drug sold by Novartis Pharma K.K. has led a special squad of Tokyo prosecutors to search the Japanese unit of the Swiss drugmaker as well as the university that conducted the research.

Tokyo Prosecutors Raid Novartis Pharma Over Drug Ads

February 19, 2014 8:01 am | News | Comments

Tokyo prosecutors raided Novartis Pharma K.K. on Wednesday over its alleged use of exaggerated advertising for a blood pressure-lowering drug, following a criminal complaint filed by the health ministry last month.       

CoStim Pharmaceuticals Acquired by Novartis

February 18, 2014 8:27 am | News | Comments

CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

Advertisement

Novartis Fourth Quarter Net Profit Rises to $2.0B

January 29, 2014 3:13 am | by John Heilprin - Associated Press - Associated Press | News | Comments

Novartis AG reported a 2 percent rise in fourth-quarter net profit Wednesday, helped by delays in generic competition to its blockbuster drugs. The Basel, Switzerland-based company said it had a net profit of $2.029 billion attributable to shareholders in the final three months of 2013.

Cell Therapeutics to Reacquire Rights to Two Anti-Cancer Compounds from Novartis

January 13, 2014 8:03 am | News | Comments

Cell Therapeutics, Inc. today announced that it has reached an agreement with Novartis to reacquire rights to two anti-cancer compounds -- pixantrone (PIXUVRI) and paclitaxel poliglumex (Opaxio). Under the terms of the previous agreement, CTI has been responsible for development and commercialization activities and expenses for both compounds to date.

Authorities in NY Sue Novartis in Kickback Scheme

January 9, 2014 8:26 am | by JAKE PEARSON, Associated Press | News | Comments

Novartis Pharmaceuticals Corp. paid kickbacks to a specialty pharmacy in exchange for recommending refills of a blood transfusion drug it produces, according to an amended complaint filed Wednesday in a civil case brought by state and federal prosecutors in New York.

Japan Files Complaint Against Novartis Over Diovan

January 9, 2014 2:40 am | by The Associated Press | News | Comments

Japan's health ministry said Thursday it has filed a criminal complaint against Novartis Pharma, alleging exaggerated advertising for the heart condition and blood-pressure lowering drug Diovan. Novartis Pharma K.K., the local unit of Swiss pharmaceutical group Novartis AG, issued an apology on...

Japanese Government to File Criminal Complaint Against Novartis

January 8, 2014 8:04 am | News | Comments

The Japanese health ministry is making final arrangements to file a criminal complaint with prosecutors against Novartis Pharma K.K. over alleged exaggerated advertising for a blood pressure-lowering drug.       

Advertisement

EU Fines Pharmaceutical Giants $22M

December 10, 2013 9:56 am | News | Comments

The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.      

Novartis Supplies MenB Vaccine, Bexsero to Princeton University

December 9, 2013 8:18 am | News | Comments

Princeton University has announced that a vaccination program with Novartis meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), began today following a campus outbreak that has affected at least eight students.

Swiss Reject Plan to Cap Managers' Pay

November 25, 2013 8:09 am | by GEIR MOULSON, Associated Press | News | Comments

Swiss voters soundly rejected on Sunday a proposal to limit the pay of companies' highest-paid managers to 12 times that of their lowest-paid workers. Switzerland is home to global business players such as pharmaceutical companies Novartis and Roche; insurance groups Zurich and Swiss Re; and banks UBS and Credit Suisse.

Bird Flu Strain Infects Human for First Time

November 14, 2013 8:27 am | by MARIA CHENG, AP Medical Writer | News | Comments

A strain of bird flu that scientists thought could not infect people has shown up in a Taiwanese woman, a nasty surprise that shows scientists must do more to spot worrisome flu strains before they ignite a global outbreak, doctors say. 

ImmunoGen Rises on Novartis Licensing Move

November 12, 2013 8:38 am | News | Comments

Shares of ImmunoGen jumped 13 percent Monday after Novartis licensed another of its potential drugs. Novartis will use ImmunoGen's antibody-drug conjugate technology to develop new treatments for cancer. ImmunoGen said the terms are similar to a licensing deal the companies announced in October.

Advertisement

Novartis to Sell Diagnostics Unit

November 11, 2013 8:49 am | News | Comments

Novartis says it is selling part of its diagnostics business to the Spanish health care company Grifols for $1.68 billion.  Novartis says the unit it acquired in 2006 as part of Chiron, an Emeryville, California-based biotech company, had sales of $565 million in 2012.

Another Study Bullish On Novartis Blood Pressure Drug

October 31, 2013 10:45 am | News | Comments

The Shiga University of Medical Science has become the third Japanese institution to conclude that a clinical study report on Novartis Pharma K.K.'s Diovan blood pressure-lowering drug contained doubtful data and was inappropriate, largely because a Novartis employee participated in the study.

Novartis Ups Full-Year Sales Outlook Despite 6% Q3 Profit Drop

October 22, 2013 2:54 am | by JOHN HEILPRIN, Associated Press | News | Comments

Novartis AG raised its full-year sales outlook because of delays in generic competition to its blockbuster blood pressure drug Diovan even though it said negative currency trends contributed to a 6 percent drop in its third-quarter net profit.

Novartis Drug Scandal May Taint Japanese Clinical Research

October 1, 2013 8:14 am | News | Comments

A health ministry panel on Monday questioned Novartis Pharma K.K.'s use of clinical research data in promoting the sale of its blood pressure-lowering drug Diovan, saying it "could constitute misleading advertisement" following the revelation that some of the data was manipulated.

Novartis' Muscle Wasting Therapy Receives FDA Breakthrough Status

August 20, 2013 9:19 am | by Matthew Dennis, First Word Pharma | News | Comments

The FDA granted breakthrough therapy designation to Novartis' experimental drug bimagrumab, also known as BYM338, for sporadic inclusion body myositis (sIBM), the company reported Tuesday. Timothy Wright, global head of development at Novartis Pharmaceuticals, remarked "with no effective therapies currently available for sIBM, bimagrumab has the potential to be the first real option for patients with this condition."

Pending Research to Offer Clues for Possible H7N9 Vaccine

August 19, 2013 9:34 am | by Helen Branswell, The Canadian Press | News | Comments

Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.

Second University Finds Data Manipulation for Novartis Drug

July 30, 2013 8:34 am | News | Comments

The Jikei University School of Medicine on Tuesday became the second Japanese university to find that clinical data had been manipulated for Novartis Pharma K.K.'s Diovan blood pressure lowering drug. The university's guest professor Seibu Mochizuki, who led its research on the drug, offered his plan to withdraw his paper on the drug carried by the British Lancet medical journal in 2007.

Drug Shows Dramatic Reduction in Seizures In Patients with Tuberous Sclerosis Complex

July 17, 2013 8:12 am | News | Comments

A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex (TSC) - a genetic disease characterized by benign tumors on multiple organ systems.

Novartis Lifts Sales Outlook Despite Q2 Profit Dip

July 17, 2013 3:14 am | by The Associated Press | News | Comments

Novartis AG raised its sales outlook for the full year on Wednesday, despite posting a 5 percent net income drop in the second quarter. The Basel-based company said it expects full-year sales to grow at a rate in the low single-digits, boosted by delays in generic...

Data Altered in Japanese Research for Novartis Blood Pressure Drug

July 12, 2013 8:23 am | News | Comments

Data employed in a clinical study on Novartis Pharma K.K.'s blockbuster blood pressure lowering drug Diovan were found to be manipulated, the Kyoto Prefectural University of Medicine announced Thursday. The research based on around 3,000 Japanese with high blood pressure was started in 2004 by Hiroaki Matsubara, a former professor at the university, who released papers between 2008 and 2012.

Novartis Heart Failure Drug Gets FDA Incentives

June 21, 2013 10:29 am | by The Associated Press | News | Comments

Novartis AG said Friday its drug serelaxin, a treatment for acute heart failure, received breakthrough therapy status from the Food and Drug Administration. The drug is intended to treat symptoms of acute heart failure episodes. Novartis said there are about 3.5 million of those in the U.S. and...

Questcor Will Pay at Least $135M for Novartis Drug

June 11, 2013 10:45 am | by The Associated Press | News | Comments

Questcor Pharmaceuticals Inc. said Tuesday it will pay at least $135 million to buy an autoimmune and inflammatory disease drug made by Novartis AG, sending its shares surging in morning trading. Questcor said it will pay $60 million upfront for Synacthen and Synacthen Depot.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading